INFOGRAPHIC: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in diabetic macular oedema (pooled results from YOSEMITE and RHINE)

Eye (Lond). 2024 Jul 29. doi: 10.1038/s41433-024-03249-0. Online ahead of print.
No abstract available